Bausch Health Cos (BHC) Projected to Post Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) is expected to be announcing its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of $0.6670 per share and revenue of $2.3733 billion for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 5:00 PM ET.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The business had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.71 billion. On average, analysts expect Bausch Health Cos to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Cos Price Performance

Shares of NYSE:BHC opened at $5.63 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.47 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a twelve month low of $4.41 and a twelve month high of $8.69. The stock’s 50 day moving average is $5.53 and its 200-day moving average is $6.21. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of 13.39 and a beta of 0.40.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Raymond James Financial restated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Weiss Ratings downgraded Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Barclays lowered their price target on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Finally, Truist Financial raised their price target on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a report on Wednesday, January 7th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bausch Health Cos presently has a consensus rating of “Reduce” and an average target price of $8.33.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Paulson & CO. Inc. raised its stake in Bausch Health Cos by 3.5% during the fourth quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after buying an additional 2,500,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Bausch Health Cos by 65.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after purchasing an additional 2,038,813 shares in the last quarter. MUFG Securities EMEA plc bought a new position in shares of Bausch Health Cos during the second quarter valued at $22,644,000. Dimensional Fund Advisors LP lifted its holdings in shares of Bausch Health Cos by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,253,995 shares of the company’s stock valued at $22,616,000 after purchasing an additional 241,546 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Bausch Health Cos by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,045,737 shares of the company’s stock valued at $14,223,000 after purchasing an additional 151,658 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.